19.00
+0.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NewAmsterdam Pharma Company
From its filings with the US Securities and Exchange Commission
NewAmsterdam Pharma Company is based in Narrden, Netherlands and is incorporated in Netherlands. Its shares trade on Nasdaq under the ticker NAMS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $22.5m and a net loss of $203.8m. At that date it held total assets of $769.3m and shareholders' equity of $683.4m.
Obicetrapib is a next-generation, oral, low-dose, highly selective CETP inhibitor that we are developing to potentially overcome the limitations of current LDL-C lowering treatments. We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved. In each of our Phase 3 clinical trials, BROADWAY and BROOKLYN, evaluating obicetrapib as an adjunct to high-intensity statin therapy, obicetrapib met its primary and secondary endpoints, with statistically significant reductions in LDL-C observed. In our Phase 3 TANDEM clinical trial, evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy, obicetrapib in combination with ezetimibe met its primary and secondary endpoints, with statistically significant reductions in LDL-C observed. In five of our Phase 2 clinical trials, TULIP, ROSE, OCEAN, ROSE2 and our Japan Phase 2b clinical trial, evaluating obicetrapib as a monotherapy or a combination therapy with ezetimibe 10 mg, we observed statistically significant LDL-C lowering. In each of these trials, side effects were similar in frequency and severity to placebo including muscle-related side effects and drug-related treatment-emergent serious adverse events (“TESAEs”). We have observed obicetrapib to be well tolerated in an aggregate of over 3,500 patients with low or moderately elevated LDL-C levels (“dyslipidemia”) in our clinical trials to date.
Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Nov 2022
- Employees
- 100
- Head office
- GOOIMEER 2-35, NARRDEN, P7, 1411 DC
- Incorporated in
- P7
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. William LewisIndependent Chairman of the Board
- Dr. Michael DavidsonChief Executive Officer, Executive Director, since 2022€1.9m
- Ms. Louise KooijInterim Chief Financial Officer
- Mr. Douglas KlingChief Operating Officer
- Dr. John KasteleinChief Scientific Officer, Non-Executive Director, since 2022€1.1m
- Ms. Juliette AudetChief Business Officer, since 2022
- Dr. Marc DitmarschChief Development Officer
- Dr. Nicholas DowningDirector
- Ms. Janneke Van Der KampTemporary Non-Executive Director
- Ms. Adele GulfoIndependent Director
- Mr. Wouter JoustraIndependent Director
- Dr. Louis LangeIndependent Director€123,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NewAmsterdam Pharma focuses on clinical-stage biopharmaceutical development for cardiovascular disease treatments.
- Obicetrapib is an oral, once-daily CETP inhibitor for LDL-C lowering as adjunct statin therapy.
- The company operates with 22 full-time employees in Naarden, Netherlands.
Weaknesses
- The company has only 22 full-time employees in a clinical-stage biopharmaceutical sector.
- NewAmsterdam Pharma is a clinical-stage company with no approved products yet.
- Obicetrapib is still in Phase 2 trials for Alzheimer's disease treatment.
Opportunities
- Obicetrapib as a fixed-dose combination with ezetimibe in ROSE2 trial for cardiovascular disease patients.
- The global market for cardiovascular disease treatments continues to grow significantly.
- NewAmsterdam Pharma aims to offer products worldwide in the Health Care sector.
Threats
- The clinical-stage biopharmaceutical sector faces high development risks for new drugs.
- Obicetrapib's Phase 2 trial for Alzheimer's disease may not succeed.
- Regulatory approvals for new cardiovascular therapies are uncertain and lengthy.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.